Alexander G. Balogh

Calgary, AB, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Historical outcomes for patients with stage IA NLPHL: RGlobal nLPHL One Working Group (GLOW) retrospective analyses.

Historical outcomes for patients with stage IA NLPHL: RGlobal nLPHL One Working Group (GLOW) retrospective analyses.

Journal: Blood advances

Published: February 05, 2026

Development and Validation of a Multimodal Artificial Intelligence-derived Digital Pathology-based Biomarker Predicting Metastasis Among Patients with Biochemical Recurrence After Radical Prostatectomy in NRG/RTOG Trials.

Development and Validation of a Multimodal Artificial Intelligence-derived Digital Pathology-based Biomarker Predicting Metastasis Among Patients with Biochemical Recurrence After Radical Prostatectomy in NRG/RTOG Trials.

Journal: European urology

Published: July 31, 2025

Quality of life results of addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy: NRG Oncology/RTOG 0534 SPPORT.

Quality of life results of addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy: NRG Oncology/RTOG 0534 SPPORT.

Journal: International journal of radiation oncology, biology, physics

Published: April 15, 2025

Long-Term Results of NRG/RTOG 9601, a Randomized Trial of Radiation With or Without Antiandrogens in Patients Receiving Salvage Prostate Bed Radiation Therapy Postprostatectomy.

Long-Term Results of NRG/RTOG 9601, a Randomized Trial of Radiation With or Without Antiandrogens in Patients Receiving Salvage Prostate Bed Radiation Therapy Postprostatectomy.

Journal: International journal of radiation oncology, biology, physics

Published: April 08, 2025

Prognostic Impact of Lymph Node Yield in a Phase III Clinical Trial (NRG/RTOG 9601) of Prostate Cancer Patients Treated With Salvage Radiation Following Prostatectomy.

Prognostic Impact of Lymph Node Yield in a Phase III Clinical Trial (NRG/RTOG 9601) of Prostate Cancer Patients Treated With Salvage Radiation Following Prostatectomy.

Journal: The Prostate

Published: February 17, 2025

Corrigendum to "Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostat Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial" [Eur. Eurol. 84(2) (2023) 156-163].

Corrigendum to "Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostat Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial" [Eur. Eurol. 84(2) (2023) 156-163].

Journal: European urology

Published: June 19, 2024

Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostate Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial.

Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostate Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial.

Journal: European urology

Published: November 07, 2022

Biochemical Failure Is Not a Surrogate End Point for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601.

Biochemical Failure Is Not a Surrogate End Point for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 23, 2022

The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial.

The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial.

Journal: Lancet (London, England)

Published: December 16, 2020

Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial.

Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 13, 2019

Serum testosterone changes in patients treated with radiation therapy alone for prostate cancer on NRG oncology RTOG 9408.

Serum testosterone changes in patients treated with radiation therapy alone for prostate cancer on NRG oncology RTOG 9408.

Journal: Advances in radiation oncology

Published: April 24, 2017

Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer.

Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer.

Journal: The New England journal of medicine

Published: February 02, 2017

Showing 1-12 of 15

Last Updated: 09/26/2026